Alnylam Pharmaceuticals (ALNY)

Generated: April 19, 2026

Yellow Dot

Statistics

Metric	Value
Last Close	$320.13
Blended Price Target	328.34
Blended Margin of Safety	2.6% Fairly Valued
Rule of 40 (Next)	52.5%
Rule of 40 (Current)	72.5%
FCF-ROIC	22.5%
Sales Growth Next Year	30.0%
Sales Growth Current Year	50.0%
Sales 3-Year Avg	48.0%
Industry	Biotechnology

Analysis

Alnylam Pharmaceuticals has undergone a fundamental transformation from a clinical-stage biotech into a profitable, revenue-generating pharmaceutical company anchored by a blockbuster launch. The approval and rapid uptake of AMVUTTRA for ATTR cardiomyopathy in 2025 represents the inflection point the company has pursued for years, generating nearly $3 billion in annual revenues and propelling the business to profitability for the first time.^[2]^[4] This is not a temporary spike but rather the beginning of a durable revenue stream serving a large, underserved patient population with a quarterly-dosing therapy that offers clear clinical and convenience advantages over prior treatments.

The company's competitive position rests on genuine technological differentiation in RNA interference therapeutics, a platform that has now produced multiple approved medicines and generated meaningful royalty streams from partner-discovered drugs like Leqvio and Qfitlia.^[4] Leadership has demonstrated disciplined capital allocation, building a cash position of approximately $2.9 billion while simultaneously funding an expanding pipeline of Phase 3 programs.^[4] The combination of a proven commercial engine, a validated technology platform, and a management team that has executed against a five-year strategic roadmap suggests Alnylam is positioned to sustain above-market growth for several years, though execution risk remains inherent in bringing new medicines to market.

What the Company Does

Alnylam Pharmaceuticals discovers, develops, and commercializes RNA interference (RNAi) therapeutics—medicines that work by silencing disease-causing genes. The company generates revenue through direct product sales of its approved medicines and through royalties and milestone payments from partners who license Alnylam-discovered compounds. The business model is that of a specialty pharmaceutical company: high R&D intensity, significant regulatory and clinical risk, but substantial margin potential once medicines reach market and achieve scale.

For full-year 2025, total net product revenues reached approximately $2.987 billion, with the TTR (transthyretin) franchise—comprising AMVUTTRA and ONPATTRO—generating $2.487 billion, or roughly 83% of product revenue.^[4] The Rare Disease segment, which includes GIVLAARI and OXLUMO, contributed approximately $500 million, or 17% of product revenue.^[4] Royalty and collaboration revenues added approximately $700 million in total revenues for the year.^[8]

Revenue Recurrence & Predictability

Alnylam's revenue is highly recurring and predictable in character. Patients with ATTR amyloidosis and other rare genetic diseases require ongoing, chronic treatment; AMVUTTRA is administered quarterly, creating a natural subscription-like revenue stream.^[1]^[2] Once a patient initiates therapy, discontinuation rates are typically low in rare disease settings, and payer coverage has been broad, reducing revenue volatility from access barriers.

The predictability is further strengthened by the fact that Alnylam's approved medicines address chronic conditions with limited alternative options. Patient demand has consistently exceeded internal forecasts, and the company has raised revenue guidance multiple times throughout 2025 as uptake accelerated.^[1]^[5] This pattern—recurring patient populations, chronic dosing, limited competition—positions Alnylam well on the recurring revenue dimension, though the company remains exposed to competitive entry and payer policy shifts over longer time horizons.

Revenue Growth Durability

Alnylam can realistically sustain high single-digit to low double-digit revenue growth for at least the next three to five years, driven by continued AMVUTTRA penetration in ATTR-CM and geographic expansion, as well as near-term Phase 3 readouts across its pipeline.^[2]^[4] The ATTR-CM market alone is estimated to include hundreds of thousands of patients globally, and U.S. penetration remains in early innings; international launches are planned, representing a significant TAM expansion opportunity.

The primary structural headwind is the eventual maturation of the AMVUTTRA franchise and potential competitive entry, particularly as other RNAi and non-RNAi modalities advance through development. However, Alnylam's pipeline includes three Phase 3 programs initiated in 2025, and the company has expanded its pipeline with four proprietary clinical trial applications, suggesting management is actively working to offset future franchise maturation.^[2] The durability of growth ultimately depends on successful Phase 3 execution and regulatory approvals over the next 24–36 months.

Economic Moat

Alnylam's moat is built on proprietary RNAi technology and manufacturing expertise that competitors have struggled to replicate at scale. The company has invested heavily in a novel enzymatic ligation-based RNAi manufacturing platform launched in 2025, which may provide cost and efficacy advantages over conventional synthesis methods.^[2] This technological differentiation, combined with an expanding patent portfolio and first-mover advantages in key indications, creates meaningful barriers to entry.

However, the moat is not impregnable. Other companies are advancing competing RNAi approaches and alternative gene-silencing technologies, and the regulatory pathway for RNAi therapeutics is now well-established, lowering barriers for new entrants. The moat is widening in the near term due to Alnylam's commercial scale and manufacturing innovation, but it will likely narrow over time as competitors bring products to market and the technology becomes more commoditized. Alnylam's ability to sustain its moat depends on continuous innovation and the successful execution of its pipeline.

Management & Leadership

Alnylam is led by CEO Yvonne Greenstreet, who took the helm in 2022 and has overseen the company's transition to profitability and the successful AMVUTTRA launch.^[2]^[4] Greenstreet's track record includes the execution of the company's five-year P5x25 strategic plan, which the company declared complete in 2025 after meeting or exceeding all stated objectives.^[4] Insider ownership levels and specific capital allocation decisions beyond the cash balance are not detailed in available recent disclosures, but the company's decision to maintain a substantial cash position while funding pipeline expansion suggests a balanced approach to shareholder returns and reinvestment.

The management team has demonstrated discipline in raising guidance only when warranted by actual performance, as evidenced by multiple upward revisions in 2025 tied to AMVUTTRA uptake acceleration.^[1]^[5] This credibility is valuable in a biotech context where execution risk is high and investor skepticism is warranted.

Key Risks

The most significant near-term risk is AMVUTTRA market saturation or slower-than-expected uptake in international markets, which could constrain revenue growth if U.S. penetration plateaus faster than anticipated. Additionally, the company faces execution risk on its three Phase 3 programs; clinical trial failures or regulatory setbacks could materially impact the growth trajectory and investor confidence.

Competitive risk is substantial. Other RNAi companies and developers of alternative gene-silencing technologies are advancing programs in ATTR and other indications. If competitors achieve superior efficacy, safety, or convenience profiles, or if they gain payer preference through pricing or other mechanisms, Alnylam's market share could erode. The company's reliance on a relatively concentrated revenue base—with AMVUTTRA and ONPATTRO representing over 80% of product revenue—creates vulnerability to any disruption in the TTR franchise.

Regulatory and reimbursement risk also warrant attention. Changes in payer coverage policies, pricing pressure from healthcare systems, or new regulatory requirements could compress margins or limit patient access. Finally, the company's profitability is recent and still modest relative to its revenue base; any significant revenue shortfall could quickly return the company to losses, which would constrain its ability to fund pipeline development.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks: 77 Quality Growth Stocks — Week of April 19, 2026 April 19, 2026